By Jewish Business News On Monday, December 4th, 2017
0 Comments

Israeli Clinical Stage Atox Bio Closes $30 Million Investment

Facebook0 Twitter Google Plus0 Pinterest0 Email Atox Bio, a clinical stage biotechnology company developing novel immunomodulators for critically ill patients, has raised $30 million. The round was led by Arix More...

By Jewish Business News On Tuesday, November 28th, 2017
0 Comments

New Israeli Cancer Therapy Demonstrates Promising Results

Facebook29 Twitter Google Plus0 Pinterest0 Email   The molecular biology lab of the Integrated Cancer Prevention Center (ICPC) at the Tel Aviv Sourasky Medical Center (TASMC), under the leadership of Prof. More...

By Jewish Business News On Monday, November 13th, 2017
0 Comments

JPMorgan, in a Rare Step, Recommends Selling Teva Shares

Facebook0 Twitter Google Plus0 Pinterest0 Email JPMorgan Bank today lowered Teva‘s rating (4,175.00.94% to the personal portfolio) and recommends selling Teva shares. This is due to concerns over the performance More...

By Jewish Business News On Monday, November 6th, 2017
0 Comments

Len Blavatnik Examines $3 Billion Investment in Teva

Facebook0 Twitter Google Plus0 Pinterest0 Email     Billionaire Len Blavatnik is considering investing $ 3 billion in Teva Pharmaceutical Industries, The Marker has learned. Blavatnik may acquire a More...

By Niva Goldberg On Thursday, October 19th, 2017
0 Comments

FDA Approves: Breakthrough in the Anti-Cancer Drug Developed by Israeli Company Kate Pharma

Facebook0 Twitter Google Plus0 Pinterest0 Email Less than two months after agreeing to buy Israeli company, Kate Pharma for $11.9 billion in cash, Pharma giant Gilead is making a breakthrough in the anti-cancer More...

By Albert Hecht On Monday, September 11th, 2017
0 Comments

New Teva CEO Kare Schultz Grants $20 Million in Cash, $13.5 Million in Securities

Facebook0 Twitter Google Plus0 Pinterest0 Email New Teva CEO Kare Schultz will earn an annual salary of $2 million and a performance-dependent bonus of 140% of the base salary – and up to a maximum of More...

By Jewish Business News On Monday, September 11th, 2017
0 Comments

Israeli Troubled Teva Appoints Kare Schultz CEO

Facebook0 Twitter Google Plus0 Pinterest0 Email   Teva‘s share price is up by more than 8% on the Tel Aviv Stock Exchange after the Israeli pharmaceutical company Named its new Kare Schultz as President More...

By Jewish Business News On Thursday, August 31st, 2017
0 Comments

Dual-Listed BiondVax to Voluntarily Delist From Tel Aviv Stock Exchange

Facebook0 Twitter Google Plus0 Pinterest0 Email BiondVax Pharmaceuticals Ltd., developer of the universal flu vaccine candidate M-001, today announced that its Board of Directors has decided to voluntarily delist More...

By Alan Gallindoss On Monday, August 28th, 2017
0 Comments

A Huge Exit on Israeli Biomed: Gilead Buys Kite Pharma for $11.9 Billion in Cash

Facebook0 Twitter Google Plus0 Pinterest0 Email   Gilead Sciences agreed on Monday to buy Kite Pharma for $11.9 billion in an all-cash deal. This acquisition is one of the biggest ever of a company More...

By Jewish Business News On Sunday, August 20th, 2017
0 Comments

Teva Launches Generic Testosterone Boost Treatment

Facebook0 Twitter Google Plus0 Pinterest0 Email Teva Pharmaceutical Industries Ltd. today announced the launch of generic Axiron (testosterone) topical solution CIII, 30 mg/1.5 mL, in the US. Testosterone topical More...

Email:

Delivered by FeedBurner